Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (54260)	4/6/2000 9:48:00 AM
From: Street Hawk	Respond to of 122087

QXLC -- I'm all over this analyst whore job! SG Cowens is like a baby crying for attention, what a bunch of ridiculous whores!!!!! This junk is up 380% on a 1K price target, THE INSANITY CONTINUES! Jesse

To: Anthony@Pacific who wrote (54260)	4/6/2000 10:38:00 AM
From: Kevin McKenzie	Read Replies (1) \| Respond to of 122087

Anthony, I have a very basic question about short-selling. I would love to start shorting more, but it seems like the execution time on a short is always abysmal. I placed an order to short MLNM at a limit of 177, when the stock was selling at 178 to 179, it even hit 180. I'm sure there are shares available to me, because I have already shorted it once today and that's the way my broker works (once you have shares available to short, you have them available for the remainder of the trading day). My 177 short just sat out there while tens of thousands of shares traded above that price. I know, had a placed a buy order at 180, I would have been filled immediately. This seems to be the rule, rather than the exception with shorting. My brokers take their own sweet time getting the short through. Is this the way it works for you? When you place a short with a price at or below the bid, do you get immediate execution most times? Any suggestions are greatly appreciated. Thanks, Kevin

To: Anthony@Pacific who wrote (54260)	4/6/2000 10:40:00 AM
From: vladz	Read Replies (1) \| Respond to of 122087

Hi Tony! thanx for STMP nice short :) do U still shorting ZIXI? vlad

To: Anthony@Pacific who wrote (54260)	4/6/2000 10:56:00 AM
From: Tassi	Read Replies (1) \| Respond to of 122087

SCLN...Good news.. This should rock " should we say "$21" NewsWire ZADAXIN Plus Chemotherapy Shows Promise for Improved Survival in Advanced Skin Cancer -------------------------------------------------------------------------------- Skin Cancer Phase 2 Results Published in Melanoma Research SAN MATEO, Calif., April 6 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed journal Melanoma Research (Volume 10, Issue 2, April 2000) suggests that ZADAXIN(R), SciClone's lead immunotherapy, increases the effectiveness of chemotherapy for metastatic malignant melanoma, the deadliest form of skin cancer and one of the most rapidly increasing types of cancer worldwide. In the open label pilot Phase 2 study of 20 stage III-IV metastatic malignant melanoma patients, there was a response rate of 50% to the combination therapy of ZADAXIN, dacarbazine (DTIC) and interferon. Five patients showed a complete response and 5 showed a partial response. Median survival among all patients was 11.5 months, with 5 patients having survived for more than 2 years, and 2 patients having survived for more than 5 years. No additional side effects or toxicities were observed from the inclusion of ZADAXIN. DTIC therapy significantly depresses a patient's immune system. In the study, ZADAXIN significantly improved the patients' immune system by restoring their natural killer (NK) cells and helper T-cells (CD4), both of which are disease fighting white blood cells. "We believe ZADAXIN immunotherapy will be a key component of multiple drug treatments for numerous cancers, infectious diseases and immune system disorders," said Donald R. Sellers, SciClone's President and Chief Executive Officer. "This study, in addition to a prior pilot phase 2 metastatic malignant melanoma study, several preclinical cancer studies, recent mechanism of action studies and our long experience in treating hepatitis patients, all validate that belief. We expect malignant melanoma to be a major focus of our new U.S. cancer program." No proven life-prolonging therapy exists for metastatic malignant melanoma, the leading cause of skin cancer death. Approximately 44,000 new cases are diagnosed each year in the U.S. and 7,300 deaths are reported. The response rate with the current drug of choice, DTIC, is approximately 20% and is usually of short duration with little impact on survival. Many patients with cancer and chronic infectious diseases have an impaired immune system. ZADAXIN significantly enhances the immune system's ability to recognize and destroy cancerous and infected cells. ZADAXIN may be a key component in the growing trend toward multiple drug cocktails for cancer and infectious diseases. ZADAXIN immunotherapy is in late-stage development for cancer and viral hepatitis worldwide. ZADAXIN now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatitis C. SciClone has filed for ZADAXIN marketing approval in 18 additional countries. SciClone Pharmaceuticals is a global specialty pharmaceutical company that develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. The Company has focused its current product development and commercialization activities on cancer, hepatitis B, hepatitis C, drug-resistant tuberculosis and cystic fibrosis. Press releases and corporate information from SciClone Pharmaceuticals are available on the Internet at www.sciclone.com or by calling the Company's Investor Relations Department at 800-724-2566. SciClone's Common Stock is listed on The Nasdaq National Market(R) under the symbol SCLN. The information in this press release includes certain forward-looking statements concerning the Company's current expectations regarding future events, including the ongoing and prospective development and commercialization of ZADAXIN immunotherapy for cancer, including metastatic malignant melanoma in the U.S., and the timing of the start and potential for success of the Company's U.S. phase 2 studies for metastatic malignant melanoma. Due to market factors and the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission. SOURCE SciClone Pharmaceuticals -0- 04/06/2000 /CONTACT: Shawn K. Singh, J.D., Chief Business Officer, 650-358-1451, or Ruth Koh, Investor Relations, 650-358-3437, both of SciClone Pharmaceuticals/ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 775865/ /Web site: sciclone.com (SCLN) CO: SciClone Pharmaceuticals ST: California IN: MTC PUB SU: JD-JJ -- SFTH023 -- 0647 04/06/2000 09:30 EDT prnewswire.com